JCR Pharmaceuticals has advanced a modified AAV gene therapy platform that achieves efficient central nervous system delivery while minimizing off-target hepatic expression. In preclinical models of lysosomal storage disorders, the platform extended survival, preserved neurological and retinal function, and reduced markers of neuroinflammation and cellular accumulation.
Key Points
- Modified AAV vectors penetrate blood-brain barrier via transferrin receptor targeting
- CNS delivery achieved with reduced liver toxicity and systemic exposure
- Extended lifespan and preserved function in multiple lysosomal storage disease models
Longevity Analysis
Lysosomal storage disorders represent a class of progressive neurodegenerative diseases where cellular regeneration and detoxification become fundamentally compromised. Achieving reliable central nervous system delivery has been a critical bottleneck; peripheral gene therapy cannot address the primary pathology when disease burden concentrates in the brain. This advance redistributes therapeutic payload to where it is needed most, reducing systemic metabolic burden and improving the probability of sustained cellular function and longevity. For individuals with these conditions, the difference between peripheral and central nervous system efficacy is the difference between disease management and disease arrest.
Original published by LT Wire.